TCN 202

Drug Profile

TCN 202

Alternative Names: TCN-202

Latest Information Update: 05 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theraclone Sciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Simplexvirus glycoprotein B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 05 Jun 2014 Development has been discontinued for Cytomegalovirus infections
  • 11 Sep 2013 Final adverse events data from a phase I trial in Cytomegalovirus infections (in volunteers) presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013)
  • 10 Sep 2013 Phase-II clinical trials in Cytomegalovirus infections (prevention) in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top